29/04/2015 - 22:00 Rociletinib, a third-generation EGFR tyrosine kinase inhibitor that targets mutations causing treatment resistance, showed sustained activity against ... More » Visit websiteField of Interest: OncologyCategories: CME-candidateCHEST || Clinical NewsCHEST || NewsCHEST || Lung CancerONCR || NewsONCR || LungFPN || NewsFPN || OncologyNews Feed: Internal Medicine News - Oncology
